Follicular lymphoma: the case for timely intervention

被引：0
作者：
McLaughlin, Peter [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
EXPERT REVIEW OF HEMATOLOGY | 2009年 / 2卷 / 03期
关键词：
chemotherapy; follicular lymphoma; radioimmunotherapy; rituximab; stem cell transplantation; NON-HODGKINS-LYMPHOMA; LOW-GRADE LYMPHOMA; BONE-MARROW-TRANSPLANTATION; B-CELL LYMPHOMA; TERM-FOLLOW-UP; INTERNATIONAL PROGNOSTIC INDEX; ANTI-CD20; MONOCLONAL-ANTIBODY; LOW-TUMOR-BURDEN; STUDY-GROUP GLSG; RANDOMIZED-TRIAL;
D O I：
10.1586/EHM.09.18
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
After decades of slow progress in the management of follicular lymphoma (FL), important strides are occurring. An aim for cure is realistic and appropriate for some patients, including those with stage I-II disease, some histologic subtypes of FL (e.g., FL grade 3b) and even some relapsing patients following allogeneic stem cell transplantation approaches. Survival outcomes are improving, probably in large part related to the inclusion of anti-CD20 monoclonal antibodies in current treatment strategies.
引用
收藏
页码：277 / 284
页数：8
相关论文
共 56 条
  • [1] Transformed lymphoma: Incidence and long-term outcome
    Al-Tourah, AJ
    Chhanabhai, M
    Hoskins, PJ
    Klasa, RJ
    Savage, KJ
    Sehn, LH
    Shenkier, TN
    Gascoyne, RD
    Connors, JM
    [J]. BLOOD, 2004, 104 (11) : 888A - 888A
  • [2] [Anonymous], 2008, WHO CLASSIFICATION T
  • [3] Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires
    Brice, P
    Bastion, Y
    Lepage, E
    Brousse, N
    Haioun, C
    Moreau, P
    Straetmans, N
    Tilly, H
    Tabah, I
    SolalCeligny, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 1110 - 1117
  • [4] The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin
    Hasford, Joerg
    Unterhalt, Michael
    Hiddemann, Wolfgang
    [J]. BLOOD, 2006, 108 (05) : 1504 - 1508
  • [5] Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma:: Results of a phase II study
    Cartron, Guillaume
    Zhao-Yang, Lu
    Baudard, Marion
    Kanouni, Tarik
    Rouille, Valerie
    Quittet, Philippe
    Klein, Bernard
    Rossi, Jean-Francois
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2725 - 2731
  • [6] SEQUENTIAL NONSURGICAL AND SURGICAL STAGING OF NON-HODGKINS LYMPHOMA
    CHABNER, BA
    JOHNSON, RE
    YOUNG, RC
    CANELLOS, GP
    HUBBARD, SP
    JOHNSON, SK
    DEVITA, VT
    [J]. ANNALS OF INTERNAL MEDICINE, 1976, 85 (02) : 149 - 154
  • [7] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [8] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation
    Colombat, P
    Salles, G
    Brousse, N
    Eftekhari, P
    Soubeyran, P
    Delwail, V
    Deconinck, E
    Haïoun, C
    Foussard, C
    Sebban, C
    Stamatoullas, A
    Milpied, N
    Boué, F
    Taillan, B
    Lederlin, P
    Najman, A
    Thièblemont, C
    Montestruc, F
    Mathieu-Boué, A
    Benzohra, A
    Solal-Céligny, P
    [J]. BLOOD, 2001, 97 (01) : 101 - 106
  • [9] Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Dave, SS
    Wright, G
    Tan, B
    Rosenwald, A
    Gascoyne, RD
    Chan, WC
    Fisher, RI
    Braziel, RM
    Rimsza, LM
    Grogan, TM
    Miller, TP
    LeBlanc, M
    Greiner, TC
    Weisenburger, DD
    Lynch, JC
    Vose, J
    Armitage, JO
    Smeland, EB
    Kvaloy, S
    Holte, H
    Delabie, J
    Connors, JM
    Lansdorp, PM
    Ouyang, Q
    Lister, TA
    Davies, AJ
    Norton, AJ
    Muller-Hermelink, HK
    Ott, G
    Campo, E
    Montserrat, E
    Wilson, WH
    Jaffe, ES
    Simon, R
    Yang, LM
    Powell, J
    Zhao, H
    Goldschmidt, N
    Chiorazzi, M
    Staudt, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21) : 2159 - 2169
  • [10] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
    Davis, TA
    Grillo-López, AJ
    White, CA
    McLaughlin, P
    Czuczman, MS
    Link, BK
    Maloney, DG
    Weaver, RL
    Rosenberg, J
    Levy, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3135 - 3143
123456